EDGAR Filing Documents for 0001737287-22-000021

Form PRE 14A - Other preliminary proxy statements:

SEC Accession No. 0001737287-22-000021

Filing Date

2022-04-14

Accepted

2022-04-14 16:10:12

Documents

Period of Report

2022-06-15

Document Format Files

Seq	Description	Document	Type	Size
1	PRE 14A	allo-20220414xdef14axpreli.htm	PRE 14A	776032
2		ceocompmixa.jpg	GRAPHIC	84484
3		otherneocompmixa.jpg	GRAPHIC	97322
4		proxycard1a.jpg	GRAPHIC	109480
5		proxycard2a.jpg	GRAPHIC	83253
6		qualificationstable_31422a.jpg	GRAPHIC	187164
	Complete submission text file	0001737287-22-000021.txt		1550802

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080

Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700

Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38693 | Film No.: 22827352
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences